|
| 37098956 | Diverse Murine Vaccinations Reveal Distinct Antibody Classes to Target Fusion Peptide and Variation in Peptide Length to Improve HIV Neutralization. | | 2023 |
| 36265510 | Bivalent SARS-CoV-2 mRNA vaccines increase breadth of neutralization and protect against the BA.5 Omicron variant in mice. | Nat Med | 2023 |
| 37989731 | Antibody-directed evolution reveals a mechanism for enhanced neutralization at the HIV-1 fusion peptide site. | | 2023 |
| 37986823 | Mucosal Adenoviral-vectored Vaccine Boosting Durably Prevents XBB.1.16 Infection in Nonhuman Primates. | bioRxiv | 2023 |
| 37886518 | Human CD4-Binding Site Antibody Elicited by Polyvalent DNA Prime-Protein Boost Vaccine Neutralizes Cross-Clade Tier-2-HIV Strains. | | 2023 |
| 37345226 | Improved pharmacokinetics of HIV-neutralizing VRC01-class antibodies achieved by reduction of net positive charge on variable domain. | | 2023 |
| 37020354 | Progress in vaccine development for infectious diseases-a Keystone Symposia report. | Ann N Y Acad Sci | 2023 |
| 36895286 | Kinetics of the Antibody Response to Symptomatic SARS-CoV-2 Infection in Vaccinated and Unvaccinated Individuals in the Blinded Phase of the mRNA-1273 COVID-19 Vaccine Efficacy Trial. | | 2023 |
| 37330602 | Examining protective effects of SARS-CoV-2 neutralizing antibodies after vaccination or monoclonal antibody administration. | | 2023 |
| 37001964 | Safety and pharmacokinetics of escalating doses of neutralising monoclonal antibody CAP256V2LS administered with and without VRC07-523LS in HIV-negative women in South Africa (CAPRISA 012B): a phase 1, dose-escalation, randomised controlled trial. | | 2023 |
| 37436900 | Improved HIV-1 neutralization breadth and potency of V2-apex antibodies by in silico design. | | 2023 |
| 37436899 | HIV-1 neutralizing antibodies elicited in humans by a prefusion-stabilized envelope trimer form a reproducible class targeting fusion peptide. | Cell Rep | 2023 |
| 36729903 | Bispecific antibody CAP256.J3LS targets V2-apex and CD4-binding sites with high breadth and potency. | MAbs | 2023 |
| 36848985 | Rhesus macaque Bcl-6/Bcl-xL B cell immortalization: Discovery of HIV-1 neutralizing antibodies from lymph node. | | 2023 |
| 37349337 | Trispecific antibody targeting HIV-1 and T cells activates and eliminates latently-infected cells in HIV/SHIV infections. | Nat Commun | 2023 |
| 35243372 | Protocol to identify and monitor key mutations of broadly neutralizing antibody lineages following sequential immunization of Ig-humanized mice. | STAR Protocols | 2022 |
| 35709309 | Broad coverage of neutralization-resistant SIV strains by second-generation SIV-specific antibodies targeting the region involved in binding CD4. | PLoS Pathogens | 2022 |
| 35589938 | Tyrosine O-sulfation proteoforms affect HIV-1 monoclonal antibody potency. | Scientific Reports | 2022 |
| 35447072 | mRNA-1273 or mRNA-Omicron boost in vaccinated macaques elicits similar B cell expansion, neutralizing responses, and protection from Omicron. | Cell | 2022 |
| 36284200 | Engineering of HIV-1 neutralizing antibody CAP256V2LS for manufacturability and improved half life. | Scientific Reports | 2022 |
| 35378757 | Primary exposure to SARS-CoV-2 variants elicits convergent epitope specificities, immunoglobulin V gene usage and public B cell clones. | bioRxiv | 2022 |
| 35547849 | Safety and Immunogenicity of a Third Dose of SARS-CoV-2 mRNA Vaccine - An Interim Analysis. | | 2022 |
| 35413243 | Structural basis for llama nanobody recognition and neutralization of HIV-1 at the CD4-binding site. | Structure | 2022 |
| 36263060 | Bivalent SARS-CoV-2 mRNA vaccines increase breadth of neutralization and protect against the BA.5 Omicron variant. | bioRxiv | 2022 |
| 36054677 | Analytical characterization of broadly neutralizing antibody CAP256LS heavy chain clipping during manufacturing development. | Biotechnology Progress | 2022 |
| 35783486 | Safety and immunogenicity of an HIV-1 prefusion-stabilized envelope trimer (Trimer 4571) vaccine in healthy adults: A first-in-human open-label, randomized, dose-escalation, phase 1 clinical trial. | eClinicalMedicine | 2022 |
| 36423012 | Assessment of Crosslinkers between Peptide Antigen and Carrier Protein for Fusion Peptide-Directed Vaccines against HIV-1. | Vaccines | 2022 |
| 36517467 | Primary exposure to SARS-CoV-2 variants elicits convergent epitope specificities, immunoglobulin V gene usage and public B cell clones. | Nat Commun | 2022 |
| 35319830 | Development of Neutralization Breadth against Diverse HIV-1 by Increasing Ab-Ag Interface on V2. | Advanced Science | 2022 |
| 35316213 | Binding and neutralizing antibody responses to SARS-CoV-2 in very young children exceed those in adults. | JCI insight | 2022 |
| 34986348 | Potent anti-viral activity of a trispecific HIV neutralizing antibody in SHIV-infected monkeys. | Cell Rep | 2022 |
| 34921774 | Protection from SARS-CoV-2 Delta one year after mRNA-1273 vaccination in rhesus macaques coincides with anamnestic antibody response in the lung. | Cell | 2022 |
| 35283191 | Antigenic analysis of the HIV-1 envelope trimer implies small differences between structural states 1 and 2. | Journal of Biological Chemistry | 2022 |
| 35020720 | Dancing in a culture of disordered eating: A feminist poststructural analysis of body and body image among young girls in the world of dance. | PLoS ONE | 2022 |
| 35081298 | SARS-CoV-2 Omicron Variant Neutralization after mRNA-1273 Booster Vaccination. | N Engl J Med | 2022 |
| 34931200 | Booster of mRNA-1273 Strengthens SARS-CoV-2 Omicron Neutralization. | medRxiv | 2021 |
| 32223538 | A rapid review of Indigenous boys' and men's sexual health in Canada. | Culture, Health and Sexuality | 2021 |
| 34237283 | Isolation and characterization of cross-neutralizing coronavirus antibodies from COVID-19+ subjects. | Cell Rep | 2021 |
| 34059428 | Feasibility and Cost of Using Instagram to Recruit Adolescents to a Remote Intervention. | Journal of Adolescent Health | 2021 |
| 33791692 | Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects. | bioRxiv | 2021 |
| 33574712 | Attitudes and Practices of a Sample of Nova Scotian Physicians for the Implementation of HIV Pre-Exposure Prophylaxis. | HIV/AIDS - Research and Palliative Care | 2021 |
| 34210892 | Ultrapotent antibodies against diverse and highly transmissible SARS-CoV-2 variants. | Science | 2021 |
| 33662277 | B cell engagement with HIV-1 founder virus envelope predicts development of broadly neutralizing antibodies. | | 2021 |
| 33453152 | Vaccination induces maturation in a mouse model of diverse unmutated VRC01-class precursors to HIV-neutralizing antibodies with >50% breadth. | Immunity | 2021 |
| 34200826 | Structures of HIV-1 Neutralizing Antibody 10E8 Delineate the Mechanistic Basis of Its Multi-Peak Behavior on Size-Exclusion Chromatography. | Antibodies (Basel) | 2021 |
| 34195680 | A diverse collection of B cells responded to HIV infection in infant BG505. | Cell Reports Medicine | 2021 |
| 33826898 | Fusion peptide priming reduces immune responses to HIV-1 envelope trimer base. | Cell Reports | 2021 |
| 34031659 | Durability of mRNA-1273-induced antibodies against SARS-CoV-2 variants. | bioRxiv | 2021 |
| 33823129 | Vaccination with prefusion-stabilized respiratory syncytial virus fusion protein induces genetically and antigenically diverse antibody responses. | Immunity | 2021 |
| 33822494 | Antibody Persistence through 6 Months after the Second Dose of mRNA-1273 Vaccine for Covid-19. | New England Journal of Medicine | 2021 |